FindTrial
Sign In

Future prospects for therapeutic strategies for brain metastases and acquired resistance in the treatment of ALK positive advanced non small cell lung cancer. A comprehensive literature review with network meta-analysis.

Future prospects for therapeutic strategies for brain metastases and acquired resistance in the treatment of ALK positive advanced non small cell lung cancer. A comprehensive literature review with network meta-analysis. - Therapeutic strategies for brain metastases and acquired resistance in the treatment of ALK positive advanced non small cell lung cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000049680
Enrollment
Unknown
Registered
2022-12-05
Start date
2022-12-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Sponsors

Showa University school of medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Phase 3 randomized trials of patients with ALK positive ALK naive advanced non-small cell lung cancer with PS of 0-2

Exclusion criteria

Exclusion criteria: Studies for children Observational studies

Design outcomes

Primary

MeasureTime frame
PFS—

Countries

Japan

Contacts

Public ContactKoichi Ando

Showa University school of medicine Division of Respirology and Allergology,Department of Medicine

koichi-a@med.showa-u.ac.jp+81-3-3784-8532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026